Im­muno­core is the lat­est to nab a pri­vate place­ment, se­cur­ing $140M to pur­sue more TCR R&D

Look­ing to se­cure a fresh raise to in­vig­o­rate R&D, Im­muno­core is putting to­geth­er a PIPE.

The for­mer Medi­gene spin­out, six months af­ter the FDA ap­proved its TCR drug tebenta­fusp, put out word Mon­day that it’s sell­ing just over 3.7 mil­lion shares of com­pa­ny stock at $37.50 each. This is go­ing to cer­tain in­vestors as a PIPE fi­nanc­ing for a to­tal of $140 mil­lion.

Shares of $IM­CR stayed con­sis­tent in pre­mar­ket trad­ing, on­ly slid­ing down half of 1% af­ter clos­ing at $43.25 a share Fri­day af­ter­noon.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER